The generic Favipiravir in India will be launched in India under the brand name ‘Favivir’, Hetero Labs, part of Hetero group announced on Wednesday
Quoting from a press release issued by the city-based drug maker, The Financial Express reported that the Drug Controller General of India (DCGI) has granted Hetero the manufacturing a
nd marketing approval for Favipiravir.
Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of COVID-19, the report said.
About Favivir
- It is an oral antiviral medication that has demonstrated positive clinical outcomes
- It improves treatment accessibility to a significant amount of COVID-19 patient population, which usually sustains mild to moderate symptoms
- It is priced at Rs 59 per tablet and is marketed and distributed by Hetero Healthcare Ltd
- The product is available from July 29 at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription, the report added.